Gland Pharma - Public Comps and Valuation Multiples

Gland Pharma Overview

About Gland Pharma

Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.

Founded

1978

HQ

Employees

4.4K+

Website

glandpharma.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $681M

LTM EBITDA $162M

EV

$3.3B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Gland Pharma Financials

As of September 2025, Gland Pharma reported last 12-month revenue of $681M and EBITDA of $162M.

In the same period, Gland Pharma generated $431M in LTM gross profit and $95.3M in net income.

See Gland Pharma valuation multiples based on analyst estimates

Gland Pharma P&L

In the most recent fiscal year, Gland Pharma reported revenue of $630M and EBITDA of $167M.

Gland Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Gland Pharma valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$681M	XXX	$630M	XXX	XXX	XXX
Gross Profit	$431M	XXX	$394M	XXX	XXX	XXX
Gross Margin	63%	XXX	63%	XXX	XXX	XXX
EBITDA	$162M	XXX	$167M	XXX	XXX	XXX
EBITDA Margin	24%	XXX	26%	XXX	XXX	XXX
EBIT	$123M	XXX	$100M	XXX	XXX	XXX
EBIT Margin	18%	XXX	16%	XXX	XXX	XXX
Net Profit	$95.3M	XXX	$78.8M	XXX	XXX	XXX
Net Margin	14%	XXX	13%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Gland Pharma including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $681M. EBITDA for the last twelve months was $162M. In the most recent fiscal year, Gland Pharma achieved $630M in revenue and $167M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$681M	Analyst estimates available to subscribers	$630M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$431M	Analyst estimates available to subscribers	$394M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	63.3% gross margin	Analyst estimates available to subscribers	62.6% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$162M	Analyst estimates available to subscribers	$167M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	23.8% EBITDA margin	Analyst estimates available to subscribers	26.5% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$123M	Analyst estimates available to subscribers	$100M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	18.0% EBIT margin	Analyst estimates available to subscribers	15.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$95.3M	Analyst estimates available to subscribers	$78.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	14.0% net profit margin	Analyst estimates available to subscribers	12.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Gland Pharma

This financial data table provides comprehensive performance metrics for Gland Pharma, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Gland Pharma generated $681M in revenue over the last twelve months.
The company achieved $162M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $431M.
Net income over the last twelve months reached $95.3M.

Fiscal Year Performance

In the most recent fiscal year, Gland Pharma reported $630M in total revenue.
Fiscal year EBITDA was $167M.
The company maintained a gross profit margin of 62.6% in the most recent fiscal year.
EBITDA margin for the fiscal year was 26.5%.
Net profit margin reached 12.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Gland Pharma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Gland Pharma Stock Performance

Gland Pharma has current market cap of INR 316B (or $3.6B), and EV of INR 290B (or $3.3B).

Market Cap Evolution

Gland Pharma Stock Data

As of October 17, 2025, Gland Pharma's stock price is INR 1918 (or $22).

See Gland Pharma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.3B	$3.6B	XXX	XXX	XXX	XXX	$0.59

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Gland Pharma Valuation Multiples

Gland Pharma's trades at 5.2x EV/Revenue multiple, and 19.5x EV/EBITDA.

See valuation multiples for Gland Pharma and 15K+ public comps

Gland Pharma Financial Valuation Multiples

As of October 17, 2025, Gland Pharma has market cap of $3.6B and EV of $3.3B.

Equity research analysts estimate Gland Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Gland Pharma has a P/E ratio of 37.4x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$3.6B	XXX	$3.6B	XXX	XXX	XXX
EV (current)	$3.3B	XXX	$3.3B	XXX	XXX	XXX
EV/Revenue	4.8x	XXX	5.2x	XXX	XXX	XXX
EV/EBITDA	20.1x	XXX	19.5x	XXX	XXX	XXX
EV/EBIT	26.6x	XXX	31.6x	XXX	XXX	XXX
EV/Gross Profit	7.6x	XXX	n/a	XXX	XXX	XXX
P/E	37.4x	XXX	44.1x	XXX	XXX	XXX
EV/FCF	61.9x	XXX	53.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Gland Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Gland Pharma Margins & Growth Rates

Gland Pharma's last 12 month revenue growth is 14%

Gland Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Gland Pharma's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Gland Pharma's rule of X is 58% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Gland Pharma and other 15K+ public comps

Gland Pharma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	14%	XXX	12%	XXX	XXX	XXX
EBITDA Margin	24%	XXX	26%	XXX	XXX	XXX
EBITDA Growth	23%	XXX	12%	XXX	XXX	XXX
Rule of 40	40%	XXX	40%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	58%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	1%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	47%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial